A European Pharmacotherapeutic Agent Roflumilast Exploring Integrated Preclinical and Clinical Evidence for SARS CoV-2 Mediated Inflammation to Organ Damage

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 2022 Mar 30

PMID 35352842

Authors

Yogendra Singh

Neeraj Kumar Fuloria

Shivkanya Fuloria

Vetriselvan Subramaniyan

Waleed Hassan Almalki

Fahad A Al-Abbasi

Imran Kazmi

Sobhit Singh Rajput

Nirmal Joshi

Gaurav Gupta

Affiliations

Soon will be listed here.

Abstract

COVID-19 has spread globally, affecting almost 160 million individuals. Elderly and pre-existing patients (such as diabetes, heart disease and asthma) seem more susceptible to severe illness with COVID-19. Roflumilast was licensed for usage in the European Union in July 2010 as a phosphodiesterase-4 (PDE4) inhibitor. Under preclinical studies, roflumilast has been shown to decrease bleomycin-induced lung fibrosis, lung hydroxyproline and right heart thickening. The current study reviewed existing data that the PDE-4 inhibitor, a roflumilast, protects renal tissues and other major organ systems after COVID-19 infection by decreasing immune cell infiltration. These immune-balancing effects of roflumilast were related to a decrease in oxidative and inflammatory burden, caspase-3 suppression and increased protein kinase A (PKA)/cyclic A.M.P. (cAMP) levels in renal and other organ tissue.

Citing Articles

The interplay of senescence and MMPs in myocardial infarction: implications for cardiac aging and therapeutics.

Balaraman A, Altamimi A, Babu M, Goyal K, Padmapriya G, Bansal P Biogerontology. 2025; 26(1):46.

PMID: 39832057 DOI: 10.1007/s10522-025-10190-6.

Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes.

Nirenjen S, Narayanan J, Tamilanban T, Subramaniyan V, Chitra V, Fuloria N Front Immunol. 2023; 14:1216321.

PMID: 37575261 PMC: 10414543. DOI: 10.3389/fimmu.2023.1216321.

A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage.

Singh Y, Fuloria N, Fuloria S, Subramaniyan V, Almalki W, Al-Abbasi F Br J Clin Pharmacol. 2022; 88(8):3562-3565.

PMID: 35352842 PMC: 9111419. DOI: 10.1111/bcp.15328.

References

Salvesen O, Davidsen J, Pottegard A, Henriksen D . Roflumilast Usage from 2010 to 2016: A Danish Nationwide Drug Utilization Study. Basic Clin Pharmacol Toxicol. 2018; 123(3):314-319. DOI: 10.1111/bcpt.13014. View

Zarbock A, Gomez H, Kellum J . Sepsis-induced acute kidney injury revisited: pathophysiology, prevention and future therapies. Curr Opin Crit Care. 2014; 20(6):588-95. PMC: 4495653. DOI: 10.1097/MCC.0000000000000153. View

McFadyen J, Stevens H, Peter K . The Emerging Threat of (Micro)Thrombosis in COVID-19 and Its Therapeutic Implications. Circ Res. 2020; 127(4):571-587. PMC: 7386875. DOI: 10.1161/CIRCRESAHA.120.317447. View

Bonato J, Meyer E, de Mendonca P, Milani H, Prickaerts J, de Oliveira R . Roflumilast protects against spatial memory impairments and exerts anti-inflammatory effects after transient global cerebral ischemia. Eur J Neurosci. 2020; 53(4):1171-1188. DOI: 10.1111/ejn.15089. View

Smyth S, Reis E, Zhang W, Fallon J, Gordon R, Coller B . Beta(3)-integrin-deficient mice but not P-selectin-deficient mice develop intimal hyperplasia after vascular injury: correlation with leukocyte recruitment to adherent platelets 1 hour after injury. Circulation. 2001; 103(20):2501-7. DOI: 10.1161/01.cir.103.20.2501. View

Zheng X, Chen J, Xie Q, Chen J, Tang H . Anti‑inflammatory effect of ciclamilast in an allergic model involving the expression of PDE4B. Mol Med Rep. 2019; 19(3):1728-1738. DOI: 10.3892/mmr.2019.9802. View

Souto F, Alves-Filho J, Turato W, Auxiliadora-Martins M, Basile-Filho A, Cunha F . Essential role of CCR2 in neutrophil tissue infiltration and multiple organ dysfunction in sepsis. Am J Respir Crit Care Med. 2010; 183(2):234-42. DOI: 10.1164/rccm.201003-0416OC. View

Hermann R, Siegmund W, Giessmann T, Westphal K, Weinbrenner A, Hauns B . The oral, once-daily phosphodiesterase 4 inhibitor roflumilast lacks relevant pharmacokinetic interactions with inhaled budesonide. J Clin Pharmacol. 2007; 47(8):1005-13. DOI: 10.1177/0091270007300950. View

Tay M, Poh C, Renia L, Macary P, Ng L . The trinity of COVID-19: immunity, inflammation and intervention. Nat Rev Immunol. 2020; 20(6):363-374. PMC: 7187672. DOI: 10.1038/s41577-020-0311-8. View

10.

Kwak H, Song J, Heo J, Yang S, Nam J, Cheon H . Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation. J Pharmacol Exp Ther. 2005; 315(3):1188-95. DOI: 10.1124/jpet.105.092056. View

11.

de Pablo R, Monserrat J, Prieto A, Alvarez-Mon M . Role of circulating lymphocytes in patients with sepsis. Biomed Res Int. 2014; 2014:671087. PMC: 4163419. DOI: 10.1155/2014/671087. View

12.

Liao M, Liu Y, Yuan J, Wen Y, Xu G, Zhao J . Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26(6):842-844. DOI: 10.1038/s41591-020-0901-9. View

13.

Wang P, Wu P, Ohleth K, Egan R, Billah M . Phosphodiesterase 4B2 is the predominant phosphodiesterase species and undergoes differential regulation of gene expression in human monocytes and neutrophils. Mol Pharmacol. 1999; 56(1):170-4. DOI: 10.1124/mol.56.1.170. View

14.

Catherine Jin S, Conti M . Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci U S A. 2002; 99(11):7628-33. PMC: 124305. DOI: 10.1073/pnas.122041599. View

15.

Buenestado A, Grassin-Delyle S, Guitard F, Naline E, Faisy C, Israel-Biet D . Roflumilast inhibits the release of chemokines and TNF-α from human lung macrophages stimulated with lipopolysaccharide. Br J Pharmacol. 2011; 165(6):1877-1890. PMC: 3372837. DOI: 10.1111/j.1476-5381.2011.01667.x. View

16.

von Bruhl M, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M . Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med. 2012; 209(4):819-35. PMC: 3328366. DOI: 10.1084/jem.20112322. View

17.

Singh Y, Fuloria N, Fuloria S, Subramaniyan V, Almalki W, Al-Abbasi F . A European pharmacotherapeutic agent roflumilast exploring integrated preclinical and clinical evidence for SARS CoV-2 mediated inflammation to organ damage. Br J Clin Pharmacol. 2022; 88(8):3562-3565. PMC: 9111419. DOI: 10.1111/bcp.15328. View

18.

Cortijo J, Iranzo A, Milara X, Mata M, Cerda-Nicolas M, Ruiz-Sauri A . Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin-induced lung injury. Br J Pharmacol. 2009; 156(3):534-44. PMC: 2697678. DOI: 10.1111/j.1476-5381.2008.00041.x. View

19.

Reusch N, De Domenico E, Bonaguro L, Schulte-Schrepping J, Bassler K, Schultze J . Neutrophils in COVID-19. Front Immunol. 2021; 12:652470. PMC: 8027077. DOI: 10.3389/fimmu.2021.652470. View

20.

Totani L, Amore C, Di Santo A, DellElba G, Piccoli A, Martelli N . Roflumilast inhibits leukocyte-platelet interactions and prevents the prothrombotic functions of polymorphonuclear leukocytes and monocytes. J Thromb Haemost. 2015; 14(1):191-204. DOI: 10.1111/jth.13173. View